Mary Broadfoot Walker: 83 years since a historical discovery

Mary Broadfoot Walker: 83 anos desde uma descoberta histórica

Vitor Martinez de Carvalho¹, Eduardo de Almeida Guimarães Nogueira¹, Gleysson Rodrigues Rosa², Yara Dadalti Fragoso¹

¹Universidade Metropolitana de Santos, Departamento de Neurologia, Santos SP, Brasil.
²Harvard Medical School, Spaulding Rehabilitation Hospital, Department of Physical Medicine and Rehabilitation, Charlestown, MA USA.

Correspondence: Yara Dadalti Fragoso; Departamento de Neurologia da Faculdade de Medicina da UNIMES; Avenida Conselheiro Nebias, 536; 11045-002 Santos SP, Brasil; E-mail: yara@bsnet.com.br

Conflict of interest: There is no conflict of interest to declare.

Received 13 June 2017; Received in final form 01 August 2017; Accepted 05 August 2017.

ABSTRACT
Mary Broadfoot Walker was a Scottish physician who, in 1935, described in great detail the effect of an anticholinesterase drug (physostigmine) on the signs and symptoms of myasthenia gravis. An original five-minutes movie is available online and the skepticism of her contemporary British medical doctors is understandable when the drastic effect of the treatment is shown in this movie. What Mary Walker taught us, more than eight decades ago, about myasthenia gravis continues to be the basis of a pharmacological diagnostic test and treatment of this disease.

Keywords: myasthenia gravis; physostigmine; neostigmine; acetylcholinesterase.

RESUMO
Mary Broadfoot Walker foi uma médica escocesa que em 1935 descreveu em grande detalhe o efeito de uma droga anticolinesterásica (fisostigmina) nos sinais e sintomas da miastenia gravis. Um filme original com cinco minutos de duração está disponível online e a reação cética dos colegas médicos contemporâneos de Mary é compreensível dado o drástico efeito terapêutico mostrado neste filme. O que Mary Walker nos ensinou mais de oito décadas atrás continua a ser a base de um teste diagnóstico farmacológico e do tratamento da miastenia gravis.

Palavras-chave: miastenia gravis; fisostigmina; neostigmina; acetilcolinesterase.

Mary Broadfoot Walker was born in Croft-an-Righ, Wigtown, Scotland, and graduated from the Medical College of Glasgow and Edinburgh in 1913. She overcame the prejudices of that era and the barriers imposed by society. During World War I, she joined the Royal Army Medical Corps and served at the 63ª General Hospital in Malta. After the war, in 1920, she became Assistant Medical Officer in 'Poor Law Service' at St. Alfege's Hospital in Greenwich. Over the years she became an academic, a doctor and a scientist and, against formidable competition in 1932, she passed the test for London Membership of the Royal College of Physicians. Her name is forever associated with the "Miracle of Saint Alfege's Hospital", that is, the effect of administration of physostigmine to patients with myasthenia gravis. Mary Walker’s clinical awareness and her calm but determined manner paved the way to the understanding and treatment of this disease, with an influence that extends to the present day.

Physostigmine is a highly toxic parasympathomimetic alkaloid extracted from the Calabar bean, which is indigenous to western Africa. It acts as a potent antagonist of atropine through a reversible anticholinesterase reaction. In 1876, Harnack demonstrated the effect of physostigmine for boosting the electrical stimulation of mammalian striated muscle¹. Sixty-two years later, Mary Walker described and showed two cases of very severe myasthenia gravis that were drastically improved through administration of physostigmine and, later on, prostigmin. Although prostigmin (neostigmine) was better tolerated by the patients, Mary highlighted that the price of nine pence per vial rendered it difficult to use in daily practice. The presentation of the dramatic improvement of the myasthenia patients took place at the clinical meeting of the Royal Society of Medicine (Neurology) at the National Hospital, Queen Square, London, on 17 February 1938, and was published in detail²-³. Mary concluded that myasthenia gravis was the pathological effect of a substance that entered the circulation and caused abnormal fatigability via the acetylcholine in the neuromuscular junction⁴. Mary’s observations were scientifically sound: she used placebo (saline) to confirm the effect of physostigmine and she established the dose-related effect of the drug. The Figure was taken from her first publication.
showing the effect of anticholinesterase agents on ptosis. The demonstration of her innovative treatment was immortalized in a movie produced in 1935, which is accessible online5.

The “Mary Walker effect” was later described and the humoral aspect of muscle tiredness was highlighted. The patient vigorously exercised the forearm with a tourniquet applied at the elbow. When the arm presented with muscle fatigue, the tourniquet was released and partial ptosis developed a few minutes later6. In addition, Mary was involved in the description of familial periodic paralysis and hypokalemia7.

Mary Walker’s papers and presentations at the Royal Society of Medicine were received with a degree of skepticism and led to great discussion among the specialists of that era. The effect of this treatment was so dramatic and, at the same time, so short-lived, that it resembled nothing previously seen. The famous neurologist Denny-Brown, who earlier compared curare poisoning to myasthenia gravis (and this was how Mary thought of physostigmine as a potential treatment), stood against Mary’s discoveries and explanations8. Others supported her findings, but she never received a Fellowship of the Royal College of Physicians and never occupied a teaching hospital position9. She was awarded the Jean Hunter Prize in 1962 “for the advancement of research into the treatment of nervous exhaustion and for her original contribution to the fundamental knowledge of the nature of myasthenia gravis, made while carrying out the routine duties of a medical officer at a large metropolitan hospital”8. Although it is now acknowledged that a German physician may have been the first to report on the effect of anticholinesterase agents in myasthenia gravis4, it was only through Mary B. Walker that the treatment became known, after detailed presentation of her results.

Mary retired to her native Scotland and died in comparative obscurity in Wigtown in 1974, at the advanced age of 86 years. She was surrounded by her cats and with neighbors who had the nicest words about the lady who had a walnut tree in her garden4,9,10.

Mary Broadfoot Walker was, perhaps, the only scientist to have made history with a “n = 1” treatment. Later she presented the second case, and “n = 2” was sufficient to convince others to try this therapy.

References